Nanobiotix (NASDAQ:NBTX) Sees Strong Trading Volume – What’s Next?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) shares saw unusually-strong trading volume on Thursday . Approximately 57,734 shares were traded during trading, a decline of 1% from the previous session’s volume of 58,351 shares.The stock last traded at $55.5750 and had previously closed at $52.04.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on NBTX shares. UBS Group boosted their target price on Nanobiotix from $3.50 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, May 1st. TD Cowen reiterated a “buy” rating on shares of Nanobiotix in a research report on Thursday, March 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a research report on Tuesday, April 21st. Finally, Guggenheim boosted their target price on Nanobiotix from $26.00 to $36.00 and gave the stock a “buy” rating in a research report on Thursday, April 2nd. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Nanobiotix has an average rating of “Moderate Buy” and a consensus price target of $26.67.

Nanobiotix Stock Down 6.5%

The business has a fifty day moving average of $35.04 and a two-hundred day moving average of $26.74.

Nanobiotix (NASDAQ:NBTX) last released its quarterly earnings results on Sunday, February 15th. The company reported ($0.23) earnings per share for the quarter. The company had revenue of $3.42 million during the quarter. Analysts expect that Nanobiotix S.A. – Sponsored ADR will post 0.53 earnings per share for the current year.

Institutional Investors Weigh In On Nanobiotix

Institutional investors and hedge funds have recently modified their holdings of the company. Optiver Holding B.V. acquired a new stake in shares of Nanobiotix in the 3rd quarter worth approximately $101,000. Royal Bank of Canada lifted its stake in Nanobiotix by 2,000.0% in the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after buying an additional 2,500 shares in the last quarter. Millennium Management LLC purchased a new stake in Nanobiotix in the 4th quarter valued at approximately $390,000. Finally, Marshall Wace LLP purchased a new stake in Nanobiotix in the 4th quarter valued at approximately $220,000. Institutional investors and hedge funds own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.